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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A39Purpose: Osteoarthritis (OA) is a degenerative joint disease and leading
cause of disability. Although Fgf18 is an emerging candidate, there are
no FDA-approved disease modifying OA drugs (DMOADs). We recently
identiﬁed the protein phosphatase Phlpp1 as an effector of chondrocyte
differentiation in vitro. Phlpp1 terminates Akt2 signaling but also
dephosphorylates and inactivates other substrates to arrest matrix
production and induce apoptosis. The purpose of this study was to
determine if Phlpp1 contributes to OA disease progression and inhibits
proper endochondral bone formation in humans and mice.
Methods: Phlpp1 Deﬁcient Mice: The Mayo Clinic Institutional Animal
Care and Use Committee approved all animal research.
Isolation, Culture, and Analysis of IMAC Cells: Immaturemouse articular
chondrocytes (IMACs) were collected from Phlpp1-/- or WT littermates.
Cultures were treated with 10 mM U0126 (Mek1/2 inhibitor), 0.1 mM
PD173074 (FgfR inhibitor), 5 mMNCS 117079 (Phlpp inhibitor) or DMSO.
Protein extracts were collected for Western blotting. Total RNA was
isolated and mRNA (2 mg) was reverse transcribed. The resulting cDNAs
were used to assay gene expression via real-time PCR.
DMMSurgeryandHistologicalAssessments:OAwassurgically inducedby
destabilizing the medial meniscus (DMM) of the right hind limb in 12
week-old, male mice (n ¼ 7 WT, 7 Phlpp1-/-). Limbs were dissected 12
weeks after surgery, ﬁxed, decalciﬁed and parafﬁn embedded. Sections
were collected every 100 mM through the entire joint and Safranin O/Fast
Green staining was performed. Osteoarthritis Research Society Interna-
tional (OARSI) scores (p¼ 0.03)were assessedby three blinded reviewers.
Immunohistochemical Staining: Tibias from 5-day old Phlpp1-/- (n¼ 5)
or WT (n ¼ 5) littermates were ﬁxed, decalciﬁed, and parafﬁn embed-
ded. Surgically discarded, de-identiﬁed articular cartilage was collected
from patients undergoing joint arthroplasty for OA or a femoral neck
fracture (FNFx) repair. Immunohistochemical (IHC) staining was per-
formed with Phlpp1 antibodies or control IgG.
Statistical Analysis: Data are shown as the mean ± standard error of the
mean (SEM). p values were determined with the student's t-test.
Results: PHLPP1was highly expressed in human articular cartilage from
OA patients, but was undetectable by IHC in articular cartilage samples
from FNFx specimens (Fig 1A). To determine if Phlpp1 contributes to OA
progression, we evaluated the effects of Phlpp1 deﬁciency on OA pro-
gression in mice using the DMM model. Phlpp1-/- mice showed sig-
niﬁcant reductions in OARSI scores and subchondral bone thickening
(Fig 1B), suggesting that loss of Phlpp1 is protective against OA
progression.
To elucidate the mechanism of this protective effect, we examined the
effects of Phlpp1 deﬁciency during endochondral bone formation.
Phlpp1 null mice exhibit reduced bone mass and growth plate abnor-
malities, including increased chondrocyte proliferation and matrix
production. Furthermore, Phlpp1 deﬁciency promoted expression of
Fgf18 (Fig. 1C), a growth factor that facilitates chondrogenesis, chon-
drocyte proliferation and cartilage regeneration in surgically-induced
models of osteoarthritis. Erk1/2 activity and chondrocyte proliferation
were also elevated. Chemical inhibition of the Fgf18 receptor, FgfR3,
abrogated the increased Erk1/2 phosphorylation observed in Phlpp1
null chondrocytes. Furthermore, blocking the function of FgfR3 or Erk1/
2 suppressed proliferation induced by Phlpp1 deﬁciency. Phlpp inhib-
itors also augmented Erk1/2 phosphorylation, matrix content and Fgf18
production (Fig 1D&E).Figure 1(A) PHLPP1 IHC in human articular cartilage from patients
undergoing total joint arthroplasty for OA or FNFx. (B) OARSI scores from
DMM surgeries performed on WT or Phlpp1-/- mice. (C) Fgf18 expression
was determined in Phlpp1-/- cells by qPCR. (D-E) Fgf18 expression and
Alcain blue staining of WT micromasses treated with the Phlpp1 inhibitor
NCS117079. *p<0.05.Conclusions: We show that PHLPP1 is highly expressed in articular
cartilage from osteoarthritic joints but not in healthy articular cartilage.
Preliminary data suggest that this increased PHLPP1 expression in OA
human articular cartilage is due to CpG island demethylation of the
Phlpp1 promoter. Importantly, inactivation of the Phlpp1 gene pro-
tected against OA progression in a surgically induced mouse model.
Chondrocyte proliferation and cartilaginous matrix production are
enhanced in Phlpp1-/- mice as well as chondrocytes treated with Phlpp
inhibitors due to increased production of Fgf18 and consequent acti-
vation of Erk1/2 activity. These results demonstrate that suppression of
Phlpp1 expression and/or activity is protective against cartilage
degeneration. Phlpp1 therefore contributes to cartilage development
and OA progression and may be a therapeutic target for OA treatment.
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SYNOVIAL FLUID CONCENTRATION OF GREMLIN1 BUT NOT
FRIZZLED-RELATED PROTEIN IS INCREASED IN PATIENTS AFTER
ACUTE KNEE INJURY
L. Zhong y, J. Leijten y, J. Post y, S. Larsson z, M. Karperien y, A. Struglics z.
yDept. of Dev.al BioEngineering, Enschede, Netherlands; zDept. of Clinical
Sci. Lund, Lund, Sweden
Purpose: Degenerative joint diseases are characterized by a disturbance
in joint homeostasis, which is poorly understood at the molecular level.
Previously, we have identiﬁed the secreted WNT antagonists dickkopf 1
homolog (Xenopus laevis) (DKK1) and frizzled-related protein (FRZB)
and the BMP antagonists Gremlin1 (GREM1) as regulators of cartilage
homeostasis by preventing hypertrophic differentiation of articular
chondrocytes, consistent with their role in articular cartilage homeo-
stasis. In this study we tested the hypothesis that health status of the
joint is reﬂected by the expression levels of FRZB and GREM1 in synovial
ﬂuid. To test this hypothesis, we performed a cross sectional analysis of
synovial ﬂuid samples collected from patients with acute and chronic
knee injury and compared these with synovial ﬂuid samples from knee
healthy controls.
Methods: Synovial ﬂuid was aspirated (Lund University, Sweden) from
patients with acute (n¼106, mean age 30 years [range 17-57], 0-77 days
from injury) and chronic (n ¼ 50, mean age 38 years [18-70] 1-37 years
after injury) knee injuries, and from knee healthy subjects (n ¼ 8, mean
age 28 years [17-85]). Synovial ﬂuid concentrations of FRZB and GREM1
were determined using ELISA (FRZB, R&D system; GREM1, Bio-connect
diagnostics). Concentration of cartilage biomarkers in synovial ﬂuid;
ARGS-aggrecan (in-house), cartilage oligomeric matrix protein (COMP;
BioVendor) and collagen epitope C2C (IBEX), and proinﬂammatory
cytokines (IL-1b, IL-6, IL-8 and TNF-a; Meso Scale Discovery) were
analyzed by immunoassays. Mann-Whitney tests for group compar-
isons and Spearman’s rank test (rS) for correlation analysis was used.
Results: Synovial ﬂuid concentration of FRZB in the acute injury group
was no different from the level in the reference group (p ¼ 0.99), but
was 2-fold (based on median concentrations) higher than the level of
the chronic injury group (p ¼ 0.023) (Fig. 1a). Synovial ﬂuid concen-
trations of GREM1 in the acute and chronic injury groups were both
higher than the level of the reference group, 2-fold (p ¼ 0.003) and 1.8-
fold (p¼ 0.031), respectively (Fig. 1b); also, in these patients the GREM1
concentration was negatively correlated to time after injury (rS ¼
-0.224, p ¼ 0.005). The FRZB and GREM1 concentrations of the acute
and chronic injury groups were not inﬂuenced by gender (p ¼ 0.550, p
¼ 0.825) or by age (rS ¼-0.146, p ¼ 0.068; rS ¼ -0.137, p ¼ 0.089),
although, the FRZB concentration was signiﬁcantly decreased in knee
healthy subjects with age (rS¼ -0.833, p ¼ 0.005). In the acute and
chronic injury groups, there was no correlation between FRZB and
GREM1 concentrations in synovial ﬂuid (rS¼ 0.04, p¼ 0.585). Also, for a
portion of the acute injury group (n ¼ 52) synovial ﬂuid FRZB concen-
trationwere correlated with COMP levels (rS¼ 0.284, p¼ 0.041) but not
with other cartilage markers (C2C p ¼ 0.55, ARGS-aggrecan p ¼ 0.311)
nor with any cytokine levels (p> 0.05 for all cytokines); the synovial
ﬂuid GREM1 concentration did not correlated with any cartilage marker
nor with cytokine levels (p > 0.05 for all markers).
Conclusions: Compared to chronic injured knees, acute injured knees
have higher synovial ﬂuid concentrations of FRZB and GREM1. Their
levels were not inﬂuenced by gender or age, indicating that the differ-
ences of FRZB and GREM1 concentrations between acute and chronic
injured knee joints depend on differences in disease conditions. Per-
sistent synovial ﬂuid levels of FRZB in acute injured knee joints might be
a way for cells trying to protect the cartilage from degradation by
Fig. 1. Analysis of synovial ﬂuid concentrations of FRZB (a) and GREM1 (b)
from patients with acute and chronic knee injuries, and from knee healthy
subjects. The boxes deﬁne the 25th and 75th percentile with a line at the
median, error bars deﬁne the 10th and 90th percentile and circles represent
individual outliers. Ref, knee healthy reference. AI, acute injury (0-77 days
after injury). CI, chronic injury (1-37 years after injury). *, p < 0.05.
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levels of GREM1 in injured knee joints (acute and chronic) suggests of
an effort to maintain cartilage homeostasis by inhibiting BMP signaling.
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RECRUITMENT OF ENDOGENOUS CHONDROGENIC PROGENITOR
CELLS FOR ARTICULAR CARTILAGE REPAIR
Y. Yu, D. Seol, B. Marc, H. Zheng, J. Buckwalter, J. Martin. Univ. of Iowa,
Iowa City, IA, United States
Purpose: Stem cell-based treatments have been explored for enhancing
articular cartilage repair in degenerating joint disease, like post-
traumatic osteoarthritis (PTOA). Various cell sources like mesenchymal
stromal cells, adipose-derived stem cells, have been used, and shown
great potential in this regard. Our previous study has identiﬁed chon-
drogenic progenitor cells (CPCs) from the surface of articular cartilage
after focal injury. These cells, which are intrinsic to cartilage can be
induced to repopulate acellular scaffolds, and then primed towards
chondrogenic differentiation restore cartilage integrity. Here, we're
trying to enhance recruitment of CPCs for repair full thickness cartilage
defect in an in vitro bovine osteochondral explant model.
Methods: 12mm diameter bovine osteochondral explants were har-
vested from mature adult cattle. 4mm full thickness defect was made
with biopsy punch. An interpenetrating polymer network (IPN) com-
posed of ﬁbrin and hyaluronic acid was fabricated with reasonable
mechanical stability. Stromal cell derived factor 1 (SDF-1) was added
into ﬁbrin precursor solution before IPN fabrication with a ﬁnal con-
centration of 200ng/ml. Fluorescent confocal imaging was taken at
different time point to record cell migration. After 10 days, explants
underwent chondrogenic differentiation up to 5 weeks. Safranin O/Fast
green staining and type II collagen immunohistochemistry (IHC)
staining were taken to evaluate regenerated cartilage. Repair tissue was
also evaluated ultrstructually and biomechanically.
Results: SDF-1 loaded IPN displayed signiﬁcantly more CPCs migration
towards focal defect, with 16.76 ± 1.6 cells/mm2 compared with IPN gel
only, which had 4.83 ± 0.6 cells/mm2 (Figure 1). Subsequent treatment
with 10 ng/ml TGFb-1 and 100 ng/ml IGF-1 in culturemedium every day
for 3-4 weeks stimulated the formation of tissue with sulfated glyco-
saminoglycan (sGAG) and water content comparable to normal carti-
lage. SDF-1 loaded IPN displayed massive PG deposition, closely
resemble native cartilage. Moreover, nearly complete bridging of the
defect by well-regenerated cartilage tissue. IPN gel only showed limited
positive staining for Safranin O, and only loosely formed patch of new
